U.S. FDA approves Skyrizi (risankizumab-rzaa) for Ulcerative Colitis (UC) expanding $AbbVie(ABBV)$ 's portfolio across Inflammatory Bowel Disease
» Submission was done Aug´23
» 4th approved indication
» recently got positive indication in EU (approval in Q3)
Image
Skyrizi UC indication approval was one of the major milestones for this year
Image
ABBV now has 3 drugs approved for UC
Humira, Rinvoq and Skyrizi all approved
UC was an $8 B global market in 2020 according to Abbvie
Image
https://x.com/DividendWave/status/1803829122646380971
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments